According to a paper published in Nature Medicine, the drug MLN8237 (or Alisertib) has reduced tumor cells, blood counts and fibrosis in mouse models of myelofibrosis. Reports John Crispino, PhD, “This new paper shows that Alisertib has an anti-tumor effect in samples of myelofibrosis, similar to what we saw in megakaryocytic leukemia.”
John Crispino is also the Scientific Advisor for the MPN Research Foundation.
Click here to read the original article from Nature, or the press release from Northwestern quoting both Dr. Crispino and Brady Stein.
There is a clinical trial for Alisertib in people with myelofibrosis currently enrolling at Northwestern. Please visit the clinicaltrials.gov listing for this study for further information including how to enroll.